IGF1R and essential thrombocythemia: ,14,20 In a previous study, we provided the in vivo validation of the therapeutic potential of agents inhibiting cAMP-effectors (e.g., the EPAC inhibitor ESI09 and SecinH3, which blocks the downstream Arf6 GTPase) and the IGF1R inhibitor AG1024 in protecting against ET-induced edema using an in vivo quantitative mouse footpad assay.22